Skip to main content

Table 1 Clinical characteristics and disease activity of patients with and without residual disease activity

From: Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice

  Total group (n = 142) Residual disease activity according to rheumatologist (n = 90) No residual disease activity according to rheumatologist (n = 52) Residual disease vs no residual disease
P value
Age mean (SD) 53.0 (12.6) 53.6 (6.3) 51.9 (13.6) 0.000
Male/female n/n 92/60 53/37 33/19 0.865
Disease duration diagnosis mean (SD) 10.3 (7.9) 11.0 (9.2) 10.1 (6.8) 0.494
on treatment > 6 months, % 93 86 94 0.618
Current only DMARD user n (%) 110 (49) 52 (58) 23 (44) 0.032
Current first TNF user n (%) 32 (22) 14 (16) 18 (35)  
Current > 1 TNF user n (%) 35 (24) 24 (27) 11 (21)  
Swollen joints 0 (0–0) 0 (0–1) 0 (0–0) 0.000
SJC of 0, n (%) 111 (77) 63 (70) 49 (94)
SJC of 1, n (%) 10 (7) 8 (9) 2 (4)
SJC of 2, n (%) 5 (3) 5 (6) 0 (0)
SJC of ≥ 3, n (%) 15 (10) 14 (16) 1 (2)
Tender joints 1 (0–2) 1 (0–3) 0 (0–0) 0.000
TJC of 0, n (%) 82 (57) 36 (40) 46 (88)
TJC of 1, n (%) 21 (13) 16 (18) 5 (10)
TJC of 2, n (%) 12 (13) 12 (13) 0 (-)
TJC of 3, n (%) 25 (17) 24 (27) 1 (2)
Number of dactylitic digits 0 (0–0) 0 (0–0) 0 (0–0) 0.017
Dactylitis count of 1, n (%) 8 (6) 8 (9) 0 (-)
Number of enthesitis points 0 (0–0) 0 (0–0) 0 (0–0) 0.001
Enthesitis count of 1, n (%) 14 (10) 14 (16) 0 (-)
Enthesitis count of 2–4, n (%) 2 (1) 2 (2) 0 (-)
VAS physician skin severity 1 (0–2) 1 (1–2.5) 1 (0–1) 0.000
VAS physician overall disease activity 1 (1–3) 2 (1–4) 1 (0–1) 0.000
VAS patient global disease activity 2 (1–6) 5 (2–7) 1 (0–2) 0.000
VAS pt pain 2 (1–6) 5 (2–7) 1 (0–2) 0.000
BASDAI 2,65 (1–4.8) 4.1 (2.5–5.9) 0.9 (0.4–1.8) 0.000
cDAPSA remission, n (%) 45 (32) 9 (10) 36 (69) 0.000
cDAPSA low disease activity, n (%) 49 (35) 34 (38) 15 (29)  
cDAPSA moderate disease activity, n (%) 35 (25) 35 (39) 0 (-)  
cDAPSA high disease activity, n (%) 6 (4) 6 (7) 0 (-)  
cDAPSA missing, n (%) 7 (5) 6 (7) 1 (2)  
  1. Values are median (IQR) unless stated otherwise. Significance of the comparisons was determined by independent sample t test for continuous variables and the Mann-Whitney U test for non-normally distributed variables. The comparisons within cDAPSA groups were determined by the Kruskall-Wallis test
  2. csDMARD conventional synthetic disease-modifying anti-rheumatic drugs, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, TNFi tumor necrosis factor inhibitor, SJC swollen joint count, TJC tender joint count, VAS visual analog scale, cDAPSA clinical Disease Activity in PsA score